TY - JOUR AU - Piette, François AU - Belmin, Joël AU - Vincent, Hélène AU - Schmidt, Nicolas AU - Pariel, Sylvie AU - Verny, Marc AU - Marquis, Caroline AU - Mely, Jean AU - Hugonot-Diener, Laurence AU - Kinet, Jean-Pierre AU - Dubreuil, Patrice AU - Moussy, Alain AU - Hermine, Olivier PY - 2011 DA - 2011/04/19 TI - Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial JO - Alzheimer's Research & Therapy SP - 16 VL - 3 IS - 2 AB - Neuroinflammation is thought to be important in Alzheimer's disease pathogenesis. Mast cells are a key component of the inflammatory network and participate in the regulation of the blood-brain barrier's permeability. Masitinib, a selective oral tyrosine kinase inhibitor, effectively inhibits the survival, migration and activity of mast cells. As the brain is rich in mast cells, the therapeutic potential of masitinib as an adjunct therapy to standard care was investigated. SN - 1758-9193 UR - https://doi.org/10.1186/alzrt75 DO - 10.1186/alzrt75 ID - Piette2011 ER -